Laurence Booth - Concepedia

Author

Laurence Booth

Virginia Commonwealth University

Also Known As

L Booth, L. A. Booth, L. Booth, Laurence A. Booth, Laurence Booth

114

Publications

3.2K

Citations

H-Index

Concepts

All Affiliations

Virginia Commonwealth University University of Richmond Puma Biotechnology (United States)Translational Genomics Research Institute The University of Texas Health Science Center at Houston

About

Laurence Booth is an author at Virginia Commonwealth University specializing in medicine, tumor biology, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	25	40	1.5K
2	Cell Biology	20	31	1K
3	Natural Sciences	3	3	81
4	Biochemistry	3	3	84
5	Health Sciences	2	2	82

Laurence Booth

Publications

2.6K

Citations

H-Index

Page 1

	Year	Citations
Lycopene and<i>β</i>-carotene protect against oxidative damage in HT29 cells at low concentrations but rapidly lose this capacity at higher doses Gordon Lowe, Laurence Booth, Andrew Young, Free Radical Research	1999	208
HDAC inhibitors enhance the immunotherapy response of melanoma cells Laurence Booth, Jane L. Roberts, Andrew Poklepovic, Oncotarget Hdac InhibitorsTumor ImmunologyMelanoma IsolatesCancer ImmunosurveillanceMedicine	2017	132
GRP78/BiP/HSPA5/Dna K is a universal therapeutic target for human disease Laurence Booth, Jane L. Roberts, Devin R. Cash, Journal of Cellular Physiology Grp78/bip/hspa5/dna KImmunologyHuman PolymorphismPathologyDisease Gene Identification	2014	97
Neratinib inhibits Hippo/YAP signaling, reduces mutant K-RAS expression, and kills pancreatic and blood cancer cells Paul Dent, Laurence Booth, Jane L. Roberts, Oncogene Tumor BiologyBlood Cancer CellsHippo/yap SignalingSignaling PathwayMedicine	2019	85
Phosphodiesterase 5 Inhibitors Enhance Chemotherapy Killing in Gastrointestinal/Genitourinary Cancer Cells Laurence Booth, Jane L. Roberts, Nichola Cruickshanks, Molecular Pharmacology	2013	71
HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody <i>in vivo</i> Laurence Booth, Jane L. Roberts, Andrew Poklepovic, Oncotarget	2017	63
GRP78/Dna K Is a Target for Nexavar/Stivarga/Votrient in the Treatment of Human Malignancies, Viral Infections and Bacterial Diseases Jane L. Roberts, Mehrad Tavallai, Aida Nourbakhsh, Journal of Cellular Physiology ImmunologyPathologyNucleic Acid Amplification TestPharmacotherapyAntiviral Drug	2015	61
PARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cells Laurence Booth, Nichola Cruickshanks, Thomas Ridder, Cancer Biology & Therapy Dna DamageChemoprevention StrategyDrug Combination ExposureCell DeathPathology	2013	61
Secondary Bile Acid Induced DNA Damage in HT29 Cells: are Free Radicals Involved? Laurence Booth, Ian Gilmore, R.F. Bilton Free Radical Research	1997	59
The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells <i>in vitro</i> and <i>in vivo</i> Laurence Booth, Jane L. Roberts, Cindy Sander, Oncotarget ImmunologyCell DeathHdac Inhibitor Ar42Ar42 Pazopanib CombinationCancer Biology	2017	58

Page 1